De novo human antibodies, raised against your target
We expose immune cells from human donor blood to your antigen in engineered immune organoids, so new antibodies are raised against it rather than selected from a fixed library. We then isolate antigen-specific B cells and recover paired antibody sequences, without animal immunization or display libraries.
Where organoids fit
| Approach | Source of diversity | Antigen-stimulated B cell response | Sequence origin |
|---|---|---|---|
| Wild-type animal immunization | Animal immune repertoire | Yes, in vivo | Non-human; typically humanized or otherwise engineered for therapeutic development |
| Humanized transgenic animals | Human antibody genes in an animal host | Yes, in vivo | Human |
| Display libraries | Pre-built synthetic or natural library | No; library enrichment against antigen | Human or synthetic |
| OrganoAb immune organoids | De novo response from human donor PBMCs | Yes, ex vivo in an engineered synthetic hydrogel environment | Human |
Fully human antibodies are available from several approaches. What distinguishes organoids is the combination of human donor B cells, a de novo response to the target, and an engineered immune environment outside an animal host. Controlled culture conditions also allow us to tailor antigen exposure and evaluate different presentation strategies for each target.
A discovery project, step by step
Target and antigen design
We agree on the target, the binding or functional profile you need, and the antigen format best suited to present relevant epitopes.
Organoid immunization
Human immune organoids in synthetic hydrogels are exposed to the antigen, with culture conditions set to support B cell activation and expansion.
B cell isolation and sequencing
Antigen-specific B cells are isolated and paired heavy and light chain sequences are recovered.
Characterization
Selected antibodies are expressed and characterized according to the plan agreed during scoping, by OrganoAb or its collaborators.
Current focus: GPCRs
We are advancing the platform for challenging antibody targets, including GPCRs and other membrane proteins. Ongoing work supported by Biolocity and the Georgia Research Alliance is evaluating GPCR antibody discovery as an initial proof of concept. We will share results here as they become available.
Questions
Who runs the work?
Projects are designed and coordinated by the OrganoAb team, and we describe the operating plan for each project during scoping.
What rights do we receive to the antibodies?
You receive a research license to evaluate the panel of antibodies from your project. For the antibodies you select, you can then obtain a commercial license, similar to licensing antibodies from a library. Specific terms are set in each agreement.
How long does a project take?
Timing depends on the target and the antigen format. We give a project-specific timeline during scoping.
Can we discuss a project confidentially?
Yes. We put a confidentiality agreement in place before any detailed discussion of your molecules or targets.